The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInsig Ai Plc Regulatory News (INSG)

Share Price Information for Insig Ai Plc (INSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 16.50
High: 16.50
Low: 16.50
Prev. Close: 16.50
INSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Insig AI Data & Technology Collaboration with FCA

24 Apr 2023 07:01

RNS Number : 1421X
Insig AI Plc
24 April 2023
 

24 April 2023

Insig AI plc

("Insig AI" or the "Company")

 

Insig AI Data and Technology Collaboration with the FCA

 

Insig AI is proud to announce that it will be providing data and software to the FCA's 2023 TechSprint, known as the Global Financial Innovation Network's (GFIN) Greenwashing TechSprint.

 

The GFIN Greenwashing TechSprint will be hosted as a virtual TechSprint, using the FCA's Digital Sandbox platform between June to September 2023 and brings together 13 international regulators so far, working with firms and businesses that have expertise in ESG & Technology.

 

Further details of the project are available on the FCA's website: https://www.fca.org.uk/firms/innovation/global-financial-innovation-network/gfin-greenwashing-techsprint

 

The goal of the project is to develop a tool or solution that could help Regulators tackle or mitigate the risks of greenwashing in financial services across the globe. The project will focus on two use cases:

a. How can technology, including AI and Machine Learning, enable regulators and supervisors verify that ESG-related product claims to retail consumers are accurate and complete; and

b. How can technology help monitor, collate and identify examples of greenwashing from financial services firms' websites, social media platforms, and other documentation or data which can also be shared across jurisdictions.

 

Insig AI will provide its data and technology platform for onboarding of partners and participants of the TechSprint via two means: supplying data to the FCA's Digital Sandbox platform and access to Insig AI's ESG Research Tool. In particular:

 

· The core data set is Insig AI's database of pdf and machine-readable corporate financial and ESG documents for approximately 4,000 companies, with entity mapping, sentence-level classification against 15 ESG issues and keyword counts; 

 

· Participants will have access to Insig AI's technology via the ESG Research Tool app, which combines machine learning, natural language processing (NLP) and Elasticsearch capability for efficient document interrogation and comparison across the database of reports; 

 

· Insig AI will facilitate the collection, tagging and addition of new corporate documents into the database if required by participants; and

 

· Training and onboarding sessions will be offered by the Insig AI ESG team to demonstrate how to use the Research Tool and to assist with data analysis.

 

Steve Cracknell, Chief Product Officer at Insig AI commented: "Our machine-readable data set and interrogation tools are a perfect complement to helping regulators and investors navigate the vast and increasing volumes of corporate disclosure data. As a technology provider to the FCA TechSprint on greenwashing, we see our role as helping deliver transparency and easy access to data through modern AI tools."

 

Matt Lowe, Manager within the Innovation Department at the FCA said: "We are pleased to have access to Insig AI's technology platform to help investigate potential greenwashing in corporate disclosure documents in the FCA's 2023 TechSprint."

 

For further information, please visit www.insg.ai or contact: 

Insig AI plc

Colm McVeigh (CEO)

Steve Cracknell (Chief Product Officer)

 

colin.mcveigh@insg.ai

Steve.cracknell@insg.ai

 

This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUORUROUUSUUR
12
Date   Source Headline
17th Apr 20247:00 amRNSDirector/PDMR Shareholding
4th Apr 20247:00 amRNSFunding facility, share allotment & PDMR dealing
2nd Apr 20247:00 amRNSTrading update & equity funding facility proposal
28th Dec 20237:00 amRNSInclusion within UN Environment Programme Tool
22nd Dec 20237:00 amRNSDirector/PDMR Shareholding
21st Dec 20237:00 amRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSInterim results
28th Nov 20237:00 amRNSAppointment of investor relations adviser and TVR
27th Nov 20237:00 amRNSCorporate development adviser and TVR
15th Nov 20237:00 amRNSDisposal, Loan Conversion, New Project Win & TVR
30th Oct 20237:00 amRNSNew Product Launch
28th Sep 20237:00 amRNSAppointment of Strategic Adviser and TVR
15th Sep 20233:56 pmRNSResult of AGM
15th Sep 20237:00 amRNSAGM Statement
30th Aug 20237:00 amRNSDirector/PDMR Shareholding
24th Aug 20237:00 amRNSDirector/PDMR Shareholding
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSFinal Results, Posting of Report and Notice of AGM
1st Aug 20234:42 pmRNSChange of Registered Office
31st Jul 20235:30 pmRNSTotal Voting Rights
4th Jul 20237:00 amRNSRevision of Convertible Loan Facility Agreement
19th May 20237:00 amRNSDirector/PDMR Shareholding
11th May 20237:00 amRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Apr 20237:00 amRNSDeath of Director
24th Apr 20237:02 amRNSEquity subscription
24th Apr 20237:01 amRNSInsig AI Data & Technology Collaboration with FCA
24th Apr 20237:00 amRNSTrading and operations update
9th Mar 20237:00 amRNSInsig AI showcase Generative AI Product Capability
6th Feb 20237:00 amRNSGenerative AI Product Capability
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
9th Jan 20237:00 amRNSConvertible Loan Facility Drawdown
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20227:00 amRNSDirector Dealing
22nd Dec 20227:00 amRNSRevision of Convertible Loan Facility Agreements
21st Dec 20227:00 amRNSDirectors gift shares to Company treasury & TVR
19th Dec 20227:00 amRNSInterim Results
8th Nov 20227:00 amRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSNew Contract Win
3rd Nov 20227:00 amRNSTrading update
26th Oct 20227:00 amRNSConvertible Loan Facility drawdown
17th Oct 20227:00 amRNSPartnership agreement with BRAIN
12th Oct 20227:00 amRNSConvertible Loan Facility Agreement and drawdown
30th Sep 202212:13 pmRNSResult of Annual General Meeting & General Meeting
30th Sep 20227:00 amRNSContract win
26th Sep 20227:00 amRNSConvertible Loan Facility drawdown
20th Sep 20227:00 amRNSChange of Registered Office
12th Sep 20227:00 amRNSConvertible Loan Facility Agreement
9th Sep 20227:00 amRNSFinal Results, Posting of Report and Notice of GM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.